Invention Grant
- Patent Title: Population of CD3-negative cells that express chemokine receptor and cell adhesion molecule, use of the same, and method for producing the same
-
Application No.: US17041061Application Date: 2019-03-26
-
Publication No.: US11987812B2Publication Date: 2024-05-21
- Inventor: Yoshikazu Yonemitsu , Yui Harada
- Applicant: GAIA BioMedicine Inc. , Yoshikazu Yonemitsu
- Applicant Address: JP Fukuoka
- Assignee: GAIA BioMedicine Inc.,Yoshikazu Yonemitsu
- Current Assignee: GAIA BioMedicine Inc.,Yoshikazu Yonemitsu
- Current Assignee Address: JP Fukuoka; JP Fukuoka
- Agency: WHDA, LLP
- Priority: JP 18059624 2018.03.27
- International Application: PCT/JP2019/012744 2019.03.26
- International Announcement: WO2019/189115A 2019.10.03
- Date entered country: 2020-10-26
- Main IPC: C12N5/0783
- IPC: C12N5/0783 ; A61K35/17 ; A61P35/00 ; C12N5/00
Abstract:
The present invention relates to an immunocyte having higher cytotoxic activity, and a pharmaceutical composition for NK cell therapies, for which high effect can be expected. The present invention provides a cell population including CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells. The present invention provides the cell population, wherein the CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cells further highly express CD11c. The present invention provides a CCR5-positive, CCR6-positive, CXCR3-positive, and CD3-negative cell, which infiltrates into a solid tumor. The present invention also provides a pharmaceutical composition containing such a cell population and a pharmaceutically acceptable additive. The present invention further provides a method for producing the aforementioned cell population.
Public/Granted literature
Information query
